<DOC>
	<DOC>NCT00167960</DOC>
	<brief_summary>To determine the impact of the restriction of the third and forth generation cephalosporins on the reduction of intestinal colonization or infection with vancomycin-resistant enterococci (VRE) in a surgical intensive care unit (SICU)</brief_summary>
	<brief_title>Study Evaluating Vancomycin-Resistant Enterococci in a Hematology Unit</brief_title>
	<detailed_description />
	<mesh_term>Bacterial Infections</mesh_term>
	<mesh_term>Gram-Positive Bacterial Infections</mesh_term>
	<mesh_term>Tazobactam</mesh_term>
	<mesh_term>Piperacillin</mesh_term>
	<mesh_term>Vancomycin</mesh_term>
	<mesh_term>beta-Lactams</mesh_term>
	<mesh_term>Piperacillin, tazobactam drug combination</mesh_term>
	<mesh_term>Penicillanic Acid</mesh_term>
	<criteria>All patients admitted to or transferred to the SICU. Eligible patients will be patients of either sex, 18 years of age or older who are admitted or transferred to the SICU. Provide written informed consent Patients who have hypersensitivity to penicillin, cephalosporins or betalactamase inhibitors. Females who are pregnant and breast feeding Any underlying conditions or noninfectious diseases that will be ultimately fatal within 48 hours. Those who have already been participating other clinical study related with antibiotics.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2007</verification_date>
	<keyword>Bacterial Infections</keyword>
</DOC>